Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386656447> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- W4386656447 abstract "Abstract Background Spending on pharmaceuticals is growing continuously with a forecast of reaching over one trillion Euro in the next five years. Also, the average price of newly launched medicines is steeply raising, thus putting pressure on public payers. With several new advanced therapies in the pipeline, there are concerns in terms of both affordability and access for all patients who may need these treatments. To manage high launch prices, public payers in Europe more and more rely on private law contractual arrangements with pharmaceutical companies, requiring significant price discounts and other types of managed-entry agreements (MEAs). Methods In spring 2021 we analysed the EURIPID database (www.euripid.eu) for occurrence and frequency of MEA in the 28 countries (AT, BE, BG, CH, CY, CZ, DK, EE, EL, ES, FI, FR, HR, HU, IE, IL, IS, IT, LV, LT, NL, NO, PT, RO, SE, SI, SK, and UK) that are covered. Euripid is a voluntary, non-profit collaboration between mainly European countries on building up and maintaining a database with information on national prices of medicinal products. Results 24 out 28 countries acknowledge the existence of MEA in their country. The highest number was identified in Italy with 1,317 agreements, followed by Latvia with 555 and Austria with 235. Seven countries use MEA as more or less standard instrument to manage their public pharmaceutical budget, whereas other countries just use it on case-by-case basis. Analysis shows that products above 100.0 Euro per unit (i.e. per shot or tablet) are much more likely to have a MEA than products with lower prices. Still, we found MEA in place also for products with a sales price per unit with <1.0 Euro. When looking into therapeutic areas, Antineoplastic and immunomodulating agents (ATC group L) including cancer medicines and immunosuppressants and medicines for the nervous system (ATC group N) dominated. Also, for some companies the likelihood of a MEA is higher than for others. Key messages Managed Entry Agreements (MEA) have become a standard tool for many public payers to manage high launch prices of pharmaceuticals. The scope of use varies widely: in some countries almost all newly launched pharmaceuticals are subject to such an agreement." @default.
- W4386656447 created "2023-09-13" @default.
- W4386656447 creator A5019856862 @default.
- W4386656447 creator A5092855598 @default.
- W4386656447 date "2021-10-01" @default.
- W4386656447 modified "2023-10-18" @default.
- W4386656447 title "How the Euripid collaboration contributes to price transparency of pharmaceuticals" @default.
- W4386656447 doi "https://doi.org/10.1093/eurpub/ckab164.576" @default.
- W4386656447 hasPublicationYear "2021" @default.
- W4386656447 type Work @default.
- W4386656447 citedByCount "0" @default.
- W4386656447 crossrefType "journal-article" @default.
- W4386656447 hasAuthorship W4386656447A5019856862 @default.
- W4386656447 hasAuthorship W4386656447A5092855598 @default.
- W4386656447 hasBestOaLocation W43866564471 @default.
- W4386656447 hasConcept C10138342 @default.
- W4386656447 hasConcept C121955636 @default.
- W4386656447 hasConcept C139719470 @default.
- W4386656447 hasConcept C144133560 @default.
- W4386656447 hasConcept C162324750 @default.
- W4386656447 hasConcept C17744445 @default.
- W4386656447 hasConcept C18547055 @default.
- W4386656447 hasConcept C199539241 @default.
- W4386656447 hasConcept C2780233690 @default.
- W4386656447 hasConcept C8326231 @default.
- W4386656447 hasConceptScore W4386656447C10138342 @default.
- W4386656447 hasConceptScore W4386656447C121955636 @default.
- W4386656447 hasConceptScore W4386656447C139719470 @default.
- W4386656447 hasConceptScore W4386656447C144133560 @default.
- W4386656447 hasConceptScore W4386656447C162324750 @default.
- W4386656447 hasConceptScore W4386656447C17744445 @default.
- W4386656447 hasConceptScore W4386656447C18547055 @default.
- W4386656447 hasConceptScore W4386656447C199539241 @default.
- W4386656447 hasConceptScore W4386656447C2780233690 @default.
- W4386656447 hasConceptScore W4386656447C8326231 @default.
- W4386656447 hasIssue "Supplement_3" @default.
- W4386656447 hasLocation W43866564471 @default.
- W4386656447 hasOpenAccess W4386656447 @default.
- W4386656447 hasPrimaryLocation W43866564471 @default.
- W4386656447 hasRelatedWork W2150417964 @default.
- W4386656447 hasRelatedWork W2280257895 @default.
- W4386656447 hasRelatedWork W2363044726 @default.
- W4386656447 hasRelatedWork W2603305904 @default.
- W4386656447 hasRelatedWork W2750739478 @default.
- W4386656447 hasRelatedWork W2969533584 @default.
- W4386656447 hasRelatedWork W2993649184 @default.
- W4386656447 hasRelatedWork W3005714303 @default.
- W4386656447 hasRelatedWork W4230610088 @default.
- W4386656447 hasRelatedWork W4283793902 @default.
- W4386656447 hasVolume "31" @default.
- W4386656447 isParatext "false" @default.
- W4386656447 isRetracted "false" @default.
- W4386656447 workType "article" @default.